Revvity and Sanofi Partner on Early Type 1 Diabetes Detection; Kihealth Secures Funding for Diabetes Test

Revvity, a Massachusetts-based diagnostics company, has announced a collaboration with pharmaceutical giant Sanofi to develop an advanced screening test for early-stage Type 1 diabetes. Meanwhile, Kihealth has raised $5 million in seed funding to support the commercial rollout of its innovative diabetes detection test.

Revvity-Sanofi Collaboration Aims to Revolutionize Type 1 Diabetes Screening

Revvity and Sanofi are joining forces to create a four-plex in vitro diagnostic test designed to detect four autoantibodies indicative of early-stage Type 1 diabetes. This collaboration aims to improve patient outcomes by enabling earlier intervention and potentially slowing the natural progression of the disease.

The new test will be based on Revvity's existing three-plex assay, which is currently limited to research use only. It will be capable of analyzing both dried blood spot and venous blood specimens, potentially increasing accessibility and ease of use.

Shirley Gil Parrado, Sanofi's global head of autoimmune Type 1 diabetes, emphasized the importance of this development, stating that the expansion of autoantibody testing to commercial platforms like Revvity GSP "may accelerate the transition to a new clinical standard of care where people with [Type 1 diabetes] are diagnosed as early as possible."

The partnership will support clinical validation and regulatory submissions for the new assay on Revvity's GSP instrument. The companies plan to seek regulatory approvals in the United States, Europe, and other jurisdictions.

Kihealth Secures $5 Million for Beta Cell Death Biomarker Test

In a separate development, Kihealth has successfully closed a $5 million seed funding round. The investment will be used to support the commercial rollout of the company's first lab-developed test, which measures biomarkers of beta cell death—an early indicator of insulin resistance and diseases such as diabetes.

Kihealth's test utilizes a simple blood draw to assess pancreatic beta cell viability. This approach enables the identification of high-risk individuals before abnormalities in glucose levels or A1c become apparent, potentially allowing for earlier intervention and management of diabetes.

The funding secured by Kihealth underscores the growing interest in innovative diagnostic technologies for diabetes and related metabolic disorders. As the incidence of diabetes continues to rise globally, early detection tools like those being developed by Revvity, Sanofi, and Kihealth may play a crucial role in improving patient outcomes and reducing the burden of the disease on healthcare systems.